Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $262.61M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.46
• Revenue Growth: -72.45%
• EPS Growth: -28.60%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 93,123,240
• 10 Day Avg. Volume: 1,354,975
• 30 Day Avg. Volume: 1,199,069
• PEG Ratio: -0.05
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 14.37
• P/FCF Ratio: -1.00
• Enterprise Value/Market Cap: -0.16
• Enterprise Value/Revenue: -4.48
• Enterprise Value/Gross Profit: -5.15
• Enterprise Value/Ebitda: 0.27
• 1Y Price Target: $4.40
• Price Target Upside: 79.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 54 Neutral
• Price Target: $2.50 ▲(2.04% Upside)

Caribou Biosciences' overall stock score is primarily impacted by its financial performance challenges, including declining revenues and persistent losses. However, the technical analysis shows positive momentum, which provides some support to the stock. The valuation remains unattractive due to negative earnings and lack of dividends.

Positive Factors

Proprietary CRISPR Platform

Caribou's proprietary CRISPR platform is a significant competitive advantage, enabling precise genetic modifications that can drive innovation in gene editing therapies and partnerships, supporting long-term growth.

Partnerships and Collaborations

Strategic partnerships and collaborations provide Caribou with diverse revenue streams and enhance its market position by leveraging external expertise and resources, fostering sustainable growth.

Low Debt Levels

Maintaining low debt levels provides Caribou with financial flexibility and reduces risk, allowing it to focus on innovation and strategic investments without the burden of high interest obligations.

Negative Factors

Declining Revenues

Declining revenues indicate potential issues in market demand or competitive positioning, which could hinder long-term growth and profitability if not addressed through strategic initiatives.

Persistent Losses

Ongoing losses reflect operational inefficiencies or high R&D costs, which may require strategic restructuring or increased revenue generation to achieve sustainable profitability.

Negative Cash Flows

Negative cash flows can limit Caribou's ability to fund operations and invest in growth opportunities without relying on external financing, potentially impacting long-term financial health.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc. is a biotechnology company focused on harnessing the power of CRISPR gene editing technology to develop innovative therapies for various diseases. The company operates primarily in the life sciences sector, offering products and services that enable researchers and developers to utilize CRISPR for gene editing applications. Caribou's core products include its proprietary CRISPR platform, which allows for precise genetic modifications, and it partners with academic institutions and pharmaceutical companies to advance cellular therapies and other biotechnological applications.

How the Company Makes Money

Caribou Biosciences generates revenue through multiple streams, including licensing agreements for its CRISPR technology, collaborations with pharmaceutical and biotechnology companies, and research grants. The company enters into partnerships that allow other firms to access its proprietary technologies for drug development, often receiving upfront payments, milestone payments based on development progress, and royalties on sales of resulting products. Additionally, Caribou may engage in grant-funded research projects that contribute to its income while furthering its technological advancements.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences faces challenges with declining revenues, substantial operational losses, and negative cash flows, which overshadow its strong equity position and low leverage ratio. The company needs to address revenue growth and operational efficiency to improve financial health and sustainability.

Income Statement

Caribou Biosciences shows declining revenue, with the TTM (Trailing-Twelve-Months) revenue at $9.918 million compared to $34.477 million the previous year, indicating a significant drop. The gross profit margin for TTM is approximately 79.41%, suggesting high efficiency in cost management relative to revenue. However, the company is struggling with significant losses as evidenced by the negative net profit margin and EBIT margin, with a TTM net income of -$147.862 million. These figures reflect challenges in scaling revenue while controlling operational costs.

Balance Sheet

The company maintains a solid equity base with a stockholders' equity of $217.222 million in the TTM period. The debt-to-equity ratio stands at 0.12, indicating low leverage and a conservative capital structure. However, the ROE is negative due to the company's net losses, impacting profitability. The equity ratio is relatively strong, suggesting a healthy buffer of equity relative to total assets. Despite the strengths in capital structure, consistent losses pose a risk to long-term financial stability.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, with TTM free cash flow at -$142.196 million, indicating cash strain from operations. The ratio of operating cash flow to net income is less than 1, highlighting inefficient cash conversion. Though the company has substantial cash reserves, the negative cash flow trends point to potential liquidity issues if losses persist without external financing or revenue improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.12M	9.99M	34.48M	13.85M	9.60M	12.36M
Gross Profit	7.94M	6.07M	30.95M	10.21M	8.61M	-22.06M
EBITDA	-148.68M	-166.62M	-112.53M	-104.78M	-66.00M	-35.21M
Net Income	-164.26M	-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet
Total Assets	220.90M	313.31M	432.21M	373.76M	442.36M	36.05M
Cash, Cash Equivalents and Short-Term Investments	183.95M	209.54M	328.83M	247.66M	375.83M	15.95M
Total Debt	25.85M	26.49M	27.11M	27.75M	259.00K	1.58M
Total Liabilities	54.77M	60.36M	63.81M	72.89M	54.53M	59.48M
Stockholders Equity	166.13M	252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow
Free Cash Flow	-135.76M	-143.08M	-104.90M	-98.02M	-35.64M	-34.53M
Operating Cash Flow	-133.11M	-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
Investing Cash Flow	115.87M	86.61M	-68.18M	-93.25M	-176.40M	6.36M
Financing Cash Flow	4.58M	16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Neutral. The current price of 2.45 is below the 20-day moving average (MA) of 2.53, above the 50-day MA of 2.15, and above the 200-day MA of 1.50, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 52.11 is Neutral, neither overbought nor oversold. The STOCH value of 22.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	―	$251.33M	―	-48.36%	―	334.02%	―
CRBU	―	$262.61M	―	-68.93%	―	-72.45%	-28.60%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMO	―	$178.16M	-2.08	-298.41%	―	565.52%	79.44%
CABA	―	$225.92M	―	-76.34%	―	―	-41.69%
VOR	―	$186.01M	―	―	―	―	-686.12%
ELTX	―	$158.48M	-2.32	-9999.00%	―	―	-4.60%

Caribou Biosciences Corporate Events

Caribou Biosciences Reports Increased Losses Amid R&D Efforts

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies using CRISPR genome-editing technology, primarily in the field of allogeneic CAR-T cell therapies for hematologic malignancies. In its latest earnings report, Caribou Biosciences reported a net loss of $54.1 million for the second quarter of 2025, compared to a net loss of $37.7 million in the same period in 2024. The company’s revenue from licensing and collaboration decreased to $2.7 million from $3.5 million year-over-year, while operating expenses increased due to impairment charges and ongoing research and development efforts. Despite the financial challenges, Caribou Biosciences continues to advance its clinical-stage therapies and maintains a cash position of $25.2 million, with marketable securities valued at $158.7 million. Looking ahead, the company aims to leverage its CRISPR technology to achieve regulatory approval and commercialization of its product candidates, while managing its financial resources to support ongoing operations.